arrow
C

Constance M. Yuan

national institutes of health (nih) - usa
H指数:47
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

To fret over FRET: Unintended fluorescence energy transfer artifacts and their implications for flow cytometry panel design and interpretation as highlighted by TRBC1/2 assays

为FRET担忧:由TRBC1/2检测试剂盒凸显的意外荧光能量转移伪影及其对流式细胞仪检测方案设计与结果解读的影响

2026-07-010
PRE
Plasticity under pressure: biology and detection of lineage switch in acute leukemia

压力下的可塑性:急性白血细胞系的生物学及转换检测

Leukemia
IF13.4
2026-06-260
PRE
CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?

CRLF2重排和B细胞急性淋巴细胞白血病中的髓外疾病:可能存在关联?

2026-02-240
OAAI
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia

10年CD22 CAR T细胞在儿童和年轻成人B细胞急性淋巴细胞白血病中的应用经验

2025-12-220
OAAI
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

伊布替尼治疗有无TP53异常的慢性淋巴细胞白血病十年:一项研究者发起的2期研究的最终报告

Blood
IF23.1
2025-12-190
PREAI
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement

关于CD19-CAR T细胞疗法后B细胞恢复定义的标准化:一项国际共识声明

2025-11-120
OAAI
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

通过靶向共价沉积在淋巴瘤细胞上的补体C3片段增强CD20单克隆抗体疗法

BLOOD
IF23.1
2025-01-072
PRE
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

一项关于达鲁珠单抗、卡非佐米和地塞米松(DKd)在高危冒烟型多发性骨髓瘤患者中的2期适应性研究

BLOOD
IF23.1
2024-11-050
PRE
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
2024-02-015
PRE
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

嵌合抗原受体T细胞作为嵌合抗原受体后T细胞衰竭的挽救疗法

2023-09-014
OAAI
Preinfusion factors impacting relapse immunophenotype following CD19 CART cells
2023-02-2066
OAAI
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

克拉屈滨与利妥昔单抗并发毛细胞白血病变体的II期研究的长期随访

2021-11-2420
OAAI